Emerging science characterizes lupus as a systemic spectrum disorder, rather than as multiple single-organ diseases. So is it time to capitalize on this progress and begin evaluating treatment options on the basis of physiologic mechanisms instead of organ involvement?
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Muangchan, C. et al. Treatment algorithms in systemic lupus erythematosus. Arthritis Care Res. (Hoboken) http://dx.doi.org/10.1002/acr.22589.
van Vollenhoven, R. F. Rituximab—shadow, illusion or light? Arthritis Res. Ther. 16, R62 (2014).
Merrill, J. T. et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 62, 222–233 (2010).
Rovin, B. H. et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 64, 1215–1226 (2012).
Condon, M. B. et al. Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann. Rheum. Dis. 72, 1280–1286 (2013).
Manzi, S. et al. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann. Rheum. Dis. 71, 1833–1838 (2012).
Brkic, Z. et al. T-helper 17 cell cytokines and interferon type I: partners in crime in systemic lupus erythematosus? Arthritis Res. Ther. 13, 228 (2011).
López, P. et al. Interferon-α-induced B-lymphocyte stimulator expression and mobilization in healthy and systemic lupus erthymatosus monocytes. Rheumatology (Oxford) 53, 2249–2258 (2014).
Kalunian, K. et al. Efficacy and safety of rontalizumab (anti-interferon α) in SLE subjects with restricted immunosuppressant use: results of a randomized, double-blind, placebo-controlled phase 2 study. Ann. Rheum Dis. (in press).
Khamashta, M. et al. Safety and efficacy of sifalimumab, an anti IFNα monoclonal antibody, in a phase 2b study of moderate to severe systemic lupus erythematosus (SLE) [abstract]. Arthritis Rheumatol. 66 (Suppl. 10), 3531 (2014).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
J.T.M. declares that she has acted as a consulted for Amgen, Anthera, Bristol-Myers Squibb, EMD Serono, GlaxoSmithKline, Genentech, Lilly, MedImmune, Pfizer and UCB, companies that have developed or are developing biologic treatments for lupus that are either mentioned or have overlapping mechanisms of action with the products mentioned in this commentary. J.T.M. also declares that she has received research grants from Bristol-Myers Squibb, Genentech and GlaxoSmithKline and speaker's honoraria from GlaxoSmithKline.
Rights and permissions
About this article
Cite this article
Merrill, J. Is SLE many single-organ diseases or an overlapping spectrum?. Nat Rev Rheumatol 11, 385–386 (2015). https://doi.org/10.1038/nrrheum.2015.61
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2015.61
